The EVICEL® Neurosurgery Phase III Study

NCT ID: NCT02457546

Last Updated: 2019-01-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 234 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-01
• Study Completion Date: 2017-10-12

Brief Summary

The objective of this study is to evaluate the safety and efficacy of EVICEL® Fibrin Sealant (Human) for use as an adjunct to sutured dural repair in cranial surgery.

Conditions

Cerebrospinal Fluid Leak

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

EVICEL Fibrin Sealant

EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen

Group Type: EXPERIMENTAL

EVICEL Fibrin Sealant

Intervention Type: BIOLOGICAL

Hydrogel sealant

The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution

Group Type: ACTIVE_COMPARATOR

Hydrogel sealant

Intervention Type: DEVICE

Interventions

EVICEL Fibrin Sealant

Intervention Type: BIOLOGICAL

Hydrogel sealant

Intervention Type: DEVICE

Other Intervention Names

fibrin sealant

Eligibility Criteria

Inclusion Criteria

• Subjects ≥18 years of age undergoing craniotomy/craniectomy for pathological processes in the supratentorial region or posterior fossa
• Subjects or legally authorized representatives must be willing to participate in the study and provide written informed consent.
• Surgical wound classification Class I
• The cuff of native dura along the craniotomy edge on each side is adequate, based on surgeon's judgment, to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product
• Presence of intra-operative cerebrospinal fluid (CSF) leakage following primary dural closure or after Valsalva maneuver

Exclusion Criteria

• Subjects with a dural lesion from a recent surgery that still has the potential for CSF leakage.
• Chemotherapy within 30-days prior to enrollment or scheduled within 7-days following surgery
• Radiation therapy to the head within 30-days prior to enrollment or scheduled within 7-days following surgery
• A previous craniotomy/craniectomy within 6 months prior to the study surgery.
• Known hypersensitivity to the components of the investigational product.
• Subjects with a known allergy to FD&C Blue #1 dye
• Subjects with an infection present at the surgical site
• Subjects with an infection indicated by any one of the following: clinical diagnosis of infection, fever, positive urine culture, positive blood culture, positive chest X-ray.
• Female subjects of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period.
• Female subjects who are nursing.
• Exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 60 day follow-up period.
• Subjects with severely altered renal or hepatic function, with a compromised immune system or autoimmune disease who can NOT receive hydrogel sealant.
• Subjects with penetratring traumatic injuries to the head with damage to the dura
• Dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff.
• Patient has a gap between durotomy edges of greater than 2mm after primary dural closure.
• Approaches that would not allow sutured dural closure such as trans-sphenoidal or trans-labirinthine-/petrosal/-mastoid. Superficial penetration of mastoid air cells are allowed.
• Use of implants made of synthetic materials coming into direct contact with dura
• Use of other fibrin sealants or PEG-based sealants on the dural closure. Approved fibrin sealants may be used for hemostasis if not in contact with the dura.
• Hydrocephalus, except occlusive hydrocephalus caused by posterior fossa pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure.
• Placement of Gliadel Wafers
• Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dural resection.
• Two or more separate cranial dural defects, including defects from ventricular cannulation and ventriculo-peritoneal shunting.
• Subjects with any other intra-operative findings identified by the surgeon that may preclude the conduct of the study procedure.
• Confined bony structures where nerves are present where neural compression may result due to swelling.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ethicon, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Kocharian, MD, PhD

Role: STUDY_DIRECTOR

Ethicon, Inc.

Locations

Clinical Investigation Site #27

Los Angeles, California, United States

Clinical Investigation Site #17

Sacramento, California, United States

Clinical Investigation Site #18

Jacksonville, Florida, United States

Clinical Investigation Site #19

Tampa, Florida, United States

Clinical Investigation Site #22

Indianapolis, Indiana, United States

Clinical Investigation Site #10

New Orleans, Louisiana, United States

Clinical Investigation Site #15

Baltimore, Maryland, United States

Clinical Investigation Site #11

Boston, Massachusetts, United States

Clinical Investigation Site #24

Ann Arbor, Michigan, United States

Clinical Investigation Site #20

New Brunswick, New Jersey, United States

Clinical Investigation Site #12

New York, New York, United States

Clinical Investigation Site #14

Cincinnati, Ohio, United States

Clinical Investigation Site #21

Philadelphia, Pennsylvania, United States

Clinical Investigation Site #51

Sydney, New South Wales, Australia

Clinical Investigation Site #54

Adelaide, South Australia, Australia

Clinical Investigation Site #50

Melbourne, Victoria, Australia

Clinical Investigation Site #52

Richmond, Victoria, Australia

Clinical Investigation Site #40

Genk, , Belgium

Clinical Investigation Site #41

Leuven, , Belgium

Clinical Investigation Site #25

Montreal, Quebec, Canada

Clinical Investigation Site #53

Auckland, , New Zealand

Clinical Investigation Site #35

London, England, United Kingdom

Clinical Investigation Site #32

Middlesbrough, England, United Kingdom

Clinical Investigation Site #35

Nottingham, England, United Kingdom

Clinical Investigation Site #30

Oxford, England, United Kingdom

Clinical Investigation Site #31

Salford, England, United Kingdom

Countries

United States; Australia; Belgium; Canada; New Zealand; United Kingdom

References

Green AL, Arnaud A, Batiller J, Eljamel S, Gauld J, Jones P, Martin D, Mehdorn M, Ohman J, Weyns F. A multicentre, prospective, randomized, controlled study to evaluate the use of a fibrin sealant as an adjunct to sutured dural repair. Br J Neurosurg. 2015 Feb;29(1):11-17. doi: 10.3109/02688697.2014.948808. Epub 2014 Aug 12.

Reference Type: BACKGROUND

PMID: 25112563 (View on PubMed)

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

2014-003954-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BIOS-14-002

Identifier Type: -

Identifier Source: org_study_id